Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 3.49B | 3.57B | 3.32B | 2.55B | 2.26B |
Gross Profit | 848.00M | 857.40M | 763.40M | 583.50M | 550.10M |
EBITDA | 472.00M | 507.30M | 477.80M | 463.20M | 351.60M |
Net Income | 142.00M | 164.60M | 155.70M | 243.10M | 24.80M |
Balance Sheet | |||||
Total Assets | 4.58B | 4.85B | 4.07B | 3.91B | 3.05B |
Cash, Cash Equivalents and Short-Term Investments | 577.00M | 708.00M | 495.50M | 559.10M | 587.20M |
Total Debt | 1.82B | 2.00B | 1.67B | 1.59B | 1.16B |
Total Liabilities | 3.20B | 3.49B | 3.03B | 3.09B | 2.39B |
Stockholders Equity | 1.20B | 1.20B | 1.00B | 785.90M | 646.10M |
Cash Flow | |||||
Free Cash Flow | 288.00M | 320.20M | 77.10M | -343.90M | 162.10M |
Operating Cash Flow | 433.00M | 499.70M | 233.80M | -91.80M | 319.00M |
Investing Cash Flow | -154.00M | -482.00M | -199.70M | -128.90M | -137.90M |
Financing Cash Flow | -409.00M | 178.00M | -83.90M | 197.70M | -17.70M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | £209.29M | 12.46 | 38.77% | 518.00% | -3.56% | -5.13% | |
75 Outperform | £640.36M | 12.98 | 14.06% | 388.46% | -1.26% | 6.56% | |
71 Outperform | £1.03B | 54.74 | 2.74% | 292.47% | -5.66% | -76.42% | |
71 Outperform | £242.94M | 20.76 | 14.84% | 146.12% | -2.36% | 117.49% | |
70 Neutral | £1.39B | 11.56 | 11.86% | 0.17% | -4.96% | -13.52% | |
67 Neutral | £2.85B | 10.42 | 4.69% | 215.06% | 2.73% | -20.56% | |
61 Neutral | £239.48M | ― | -6.40% | ― | -21.84% | 10.56% |
RHI Magnesita announced it will release its half-year results for the period ending 30 June 2025 on 30 July 2025. The announcement will be accompanied by a webcast presentation for investors and analysts, highlighting the company’s ongoing commitment to transparency and engagement with stakeholders. This release is expected to provide insights into the company’s performance and strategic direction, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (GB:RHIM) stock is a Buy with a £4400.00 price target. To see the full list of analyst forecasts on RHI Magnesita NV stock, see the GB:RHIM Stock Forecast page.
RHI Magnesita announced the appointment of Janet Ashdown as a Non-Executive Director and Chair-elect of the Remuneration Committee at Synthomer Plc, effective from July 1, 2025. This strategic move highlights RHI Magnesita’s commitment to strengthening its governance and leadership, potentially enhancing its industry positioning and stakeholder confidence.
The most recent analyst rating on (GB:RHIM) stock is a Hold with a £4000.00 price target. To see the full list of analyst forecasts on RHI Magnesita NV stock, see the GB:RHIM Stock Forecast page.
RHI Magnesita N.V. announced that as of May 31, 2025, its issued share capital comprises 47,294,191 ordinary shares, with an additional 2,183,514 shares held in treasury. This update is significant for shareholders and those with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules, as it affects the calculation of their interests in the company.
The most recent analyst rating on (GB:RHIM) stock is a Buy with a £4150.00 price target. To see the full list of analyst forecasts on RHI Magnesita NV stock, see the GB:RHIM Stock Forecast page.
RHI Magnesita N.V. announced that a person discharging managerial responsibilities exercised share options over 6,017 ordinary shares, which were subsequently sold. The transaction was part of the company’s Long Term Incentive Plan, with shares transferred from the company’s treasury account. This move reflects the company’s adherence to its incentive plans and regulatory compliance, potentially impacting its stock liquidity and market perception.
The most recent analyst rating on (GB:RHIM) stock is a Buy with a £4150.00 price target. To see the full list of analyst forecasts on RHI Magnesita NV stock, see the GB:RHIM Stock Forecast page.
RHI Magnesita announced the appointment of Jann Brown as a Non-Executive Director on its board, effective from May 22, 2025. This strategic move is expected to enhance the company’s governance and potentially strengthen its market position, reflecting its ongoing commitment to leadership and growth in the refractory industry.
The most recent analyst rating on (GB:RHIM) stock is a Buy with a £4150.00 price target. To see the full list of analyst forecasts on RHI Magnesita NV stock, see the GB:RHIM Stock Forecast page.
RHI Magnesita announced that all voting resolutions proposed at its Annual General Meeting on May 7, 2025, were passed by the required majority. Key resolutions included the adoption of the annual accounts, declaration of a final dividend, re-election of directors, and re-appointment of the external auditor. These decisions reflect strong shareholder support and are expected to reinforce the company’s strategic direction and operational stability.
RHI Magnesita’s Q1 2025 trading update reveals increased downside risks due to weak performance expectations and global trade tensions. The company faced challenging trading conditions with lower sales volumes and reduced margins, prompting cost-saving measures and a price increase program to restore profitability. The closure of the Wetro plant in Germany and the acquisition of Resco in North America are key strategic moves. Despite a rise in net debt, the company expects improved performance in the second half of the year, although macroeconomic volatility poses risks to achieving its full-year guidance.
RHI Magnesita has announced its total voting rights as of April 30, 2025, with an issued share capital of 47,279,213 ordinary shares, excluding 2,198,492 shares held in treasury. This figure is crucial for shareholders and others with notification obligations to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.